The widespread use of prostate-specific antigen (PSA) screening has led to earlier detection and a dramatic reduction in overall mortality of prostate cancer;however it has also resulted in over diagnosis and over treatment of indolent disease. PSA-triggered biopsies are generally performed to improve specificity, but biopsies have also proven to be inaccurate in the staging of prostate cancer because of the inherent heterogeneity of most tumors. We hypothesize that molecular imaging strategies offer an opportunity for improved differential diagnoses and staging, due to the ability to provide more accurate information on the location, size, extent, and grade of disease. The overall objective of this proposal is to develop tumor-targeted Gd-conjugated dendrimer nanoclusters (DNCs) as an ultra-sensitive T1 magnetic resonance (MR) imaging contrast agents for the specific detection of prostate cancer. DNCs will be conjugated to the scFv of antibody F77, which recognizes a unique glycolipid antigen that is specifically expressed on the cell surface of both androgen-dependent and androgen-independent prostate cancer cells.
The specific aims for the proposal are (1) to synthesize biodegradable, Gd-conjugated DNCs;(2) evaluate the toxicity, specific targeting capabilities, and uptake of tumor-targeted DNCS in culture;and (3) evaluate the ability to detect tumors in orthotopic mouse models of prostate cancer. The long-term goal of this proposal is to develop a contrast agent that can provide improved differential diagnoses and staging of prostate cancer and thus reduce or eliminate the over-treatment of the disease.
The overall objective of this proposal is to develop tumor-targeted Gd-conjugated dendrimer nanoclusters (DNCs) as an ultra-sensitive T1 magnetic resonance (MR) imaging contrast agents for the specific detection of prostate cancer. DNCs will be conjugated to the scFv of antibody F77, which recognizes a unique glycolipid antigen that is specifically expressed on the cell surface of both androgen-dependent and androgen-independent prostate cancer cells.
|McQuade, Casey; Al Zaki, Ajlan; Desai, Yaanik et al. (2015) A multifunctional nanoplatform for imaging, radiotherapy, and the prediction of therapeutic response. Small 11:834-43|
|Zhang, Xuemei; Zajac, Allison L; Huang, Lingyan et al. (2014) Imaging the directed transport of single engineered RNA transcripts in real-time using ratiometric bimolecular beacons. PLoS One 9:e85813|
|Lajud, Shayanne A; Nagda, Danish A; Qiao, Peter et al. (2014) A Novel Chitosan-Hydrogel-Based Nanoparticle Delivery System for Local Inner Ear Application. Otol Neurotol :|
|Elias, Andrew; Crayton, Samuel H; Warden-Rothman, Robert et al. (2014) Quantitative comparison of tumor delivery for multiple targeted nanoparticles simultaneously by multiplex ICP-MS. Sci Rep 4:5840|
|Cheng, Zhiliang; Al Zaki, Ajlan; Jones, Ian W et al. (2014) Stabilized porous liposomes with encapsulated Gd-labeled dextran as a highly efficient MRI contrast agent. Chem Commun (Camb) 50:2502-4|
|de Barros, Andre Luis Branco; Chacko, Ann-Marie; Mikitsh, John L et al. (2014) Assessment of global cardiac uptake of radiolabeled iron oxide nanoparticles in apolipoprotein-E-deficient mice: implications for imaging cardiovascular inflammation. Mol Imaging Biol 16:330-9|
|Cheng, Zhiliang; Tsourkas, Andrew (2014) Monitoring phospholipase A? activity with Gd-encapsulated phospholipid liposomes. Sci Rep 4:6958|
|Hui, James Zhe; Al Zaki, Ajlan; Cheng, Zhiliang et al. (2014) Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles. Small 10:3354-63|
|Arumugam, Selvanathan; Popik, Vladimir V (2014) Sequential "click" - "photo-click" cross-linker for catalyst-free ligation of azide-tagged substrates. J Org Chem 79:2702-8|
|Nwe, Kido; Huang, Ching-Hui; Tsourkas, Andrew (2013) Gd-labeled glycol chitosan as a pH-responsive magnetic resonance imaging agent for detecting acidic tumor microenvironments. J Med Chem 56:7862-9|
Showing the most recent 10 out of 14 publications